BioSpace News Archive

Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the first site has been activated to enroll patients in REDWOOD-HCM OLE, an open-label extension clinical study designed to assess the long-term safety and tolerability of CK-3773274 (CK-274) in patients with symptomatic obstructive HCM (oHCM). Eligible patients have completed participation in REDWOOD-HCM, the Phase 2 clinical trial of CK-274,

Plan to report initial safety and activity data from Phase 1 study of NTLA-2001, a potentially curative single-dose therapy for transthyretin amyloidosis (ATTR), in mid-2021 On track to submit an IND or IND-equivalent in mid-2021 to advance NTLA-5001 for acute myeloid leukemia (AML) Expect to submit an IND or IND-equivalent in 2H 2021 for NTLA-2002 for hereditary angioedema (HAE) Ended the quarter with a strong cash position of $600.8 million

Syneos Health®, the only fully integrated biopharmaceutical solutions organization, announced that Lynn Hamilton, Senior Director, Clinical Operations and Clinical Development Services, and Katya Magonova, MBA, Senior Engagement Manager, Commercial Advisory Group, have been recognized by the Healthcare Businesswomen’s Association as exemplary female leaders in the biopharmaceutical industry for 2021.

Humacyte, Inc., a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, today announced that clinical investigators and senior leadership will present at five scientific and medical events in May 2021.

--ARIKAYCE® (amikacin liposome inhalation suspension) Approved in Japan for Patients with NTM Lung Disease Caused by MAC Who Did Not Sufficiently Respond to Prior Treatment with a Multidrug Regimen--

Infinity Pharmaceuticals, Inc . (NASDAQ: INFI), a clinical-stage biotechnology company developing eganelisib, a potentially first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic that addresses a fundamental biologic mechanism of immune suppression in cancer, will host a conference call on Thursday, May 13 th 2021 at 4:30pm ET to report its financial results for the first quarter of 2021.

– Seralutinib and GB004 continue to progress through ongoing Phase 2 TORREY and SHIFT-UC clinical trials for Pulmonary Arterial Hypertension (PAH) and Ulcerative Colitis (UC), respectively – – Cash, cash equivalents and marketable securities totaled $453 million as of March 31, 2021 –

First ever Phase 2 clinical trial designed to evaluate the effect of cannabis against an opioid treatment QIXLEEF has the potential to transform the pain market

AxcellaAxcellaAxcellaAxcella, a clinical-stage biotechnology company pioneering a new approach to treat complex diseases and improve health using endogenous metabolic modulator compositions, announced financial results for the first quarter ended March 31, 2021 and provided a business update.

Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver disease arising from non-alcoholic steatohepatitis (“NASH”), today announced that it has completed recruitment for its Phase 2a ‘AMBITION’ clinical trial, with all NASH patients in the 225 mg CRV431 dosing cohort now enrolled.